Jubilant Ingrevia Ltd
NSE:JUBLINGREA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3.3), the stock would be worth ₹629.35 (10% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.7 | ₹702.75 |
0%
|
| 3-Year Average | 3.3 | ₹629.35 |
-10%
|
| 5-Year Average | 3.3 | ₹634.84 |
-10%
|
| Industry Average | 2.8 | ₹539.09 |
-23%
|
| Country Average | 3.3 | ₹624.41 |
-11%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Jubilant Ingrevia Ltd
NSE:JUBLINGREA
|
111B INR | 3.7 | 41.9 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
13.5T JPY | 3 | 28.4 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
78.7B USD | 17.1 | 30.7 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
72.4B USD | 7.4 | 34.9 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | 0.7 | 10.5 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
282.8B CNY | 2.6 | 21.5 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
25.7B CHF | 5.6 | 23.9 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 11.8 | 54.8 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.3T INR | 11.9 | 60.7 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
23.4B USD | 2.9 | 14.8 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 2.7 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.1 |
| Median | 3.3 |
| 70th Percentile | 5.5 |
| Max | 4 699.1 |
Other Multiples
Jubilant Ingrevia Ltd
Glance View
Jubilant Ingrevia Ltd. emerges as an intriguing player within the specialty chemicals sector, weaving together an intricate tapestry of chemistry and innovation to carve its niche. Established as a dynamic offshoot of the Jubilant Bhartia Group, this company beautifully integrates forward and backward value chains to deliver a diverse palette of products. Focused on addressing the needs of the life sciences and nutrition sectors among others, Jubilant Ingrevia hinges its operations on three core segments: specialty chemicals, nutrition and health solutions, and life science chemicals. The company brings to the table a wide array of high-performance chemical ingredients and nutritional solutions that cater to industries ranging from pharmaceuticals to personal care. The financial heartbeat of Jubilant Ingrevia beats through its strategic positioning within these integrated operations. By anchoring its processes in innovation and sustainability, the firm efficiently churns out a variety of value-added products. Within the specialty chemicals space, Jubilant leverages complex scientific processes to refine raw materials into specialty polymer intermediates and fine ingredients that serve as critical building blocks for clients' products. Meanwhile, its nutrition and health solutions segment thrives on the rising global demand for wellness-focused products, supplying a range of ingredients that bolster human and animal nutrition. Additionally, life science chemicals serve as the bedrock of the company's revenue, providing essential materials for pharmaceuticals and agrochemicals. Altogether, Jubilant Ingrevia capitalizes on its end-to-end service capabilities, strong research and development, and robust manufacturing frameworks to sustain its competitive edge and fuel its financial growth.